Bertuzzi Clara, Righi Simona, Motta Giovanna, Rossi Maura, Carella Matteo, Gabrielli Giulia, Facchini Elena, Baldassarre Maurizio, Prete Arcangelo, Zinzani Pier Luigi, Mascolo Massimo, Agostinelli Claudio, Sabattini Elena
Haematopathology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, 40138 Bologna, Italy.
Department of Medical and Surgical Sciences, University of Bologna, 40138 Bologna, Italy.
Cancers (Basel). 2024 Dec 18;16(24):4210. doi: 10.3390/cancers16244210.
Classical Hodgkin's lymphoma (cHL) in adolescents between 15 and 18 years old shows a higher disease-related mortality, and the overall prognosis is worse than in both children and adults.
We investigated the immune checkpoint inhibitors (ICPIs) therapeutic targets and specific T-regulatory and cytotoxic T-cell subsets in the subgroup of adolescent cHL patients, and we challenged their prognostic power.
We retrieved formalin-fixed paraffin-embedded (FFPE) tissue of adolescent patients diagnosed with cHL and tested by immunohistochemistry the immune checkpoint molecules CTLA-4, LAG-3, PD-1, and PDL1 as well as the biological markers FOXP3 and CD8.
All the cases of our cohort expressed the immune checkpoint molecules CTLA-4, LAG-3, and PD-1 in microenvironment (ME), and the number of PD1+ cells was strongly associated with advanced disease, being higher in stage III/IV, indicating a possible role in the progression of cHL. A higher risk of recurrence and progression occurred in patients with lower amount of CD8+ microenvironmental T-cells at diagnosis (67.14 ± 27.23 vs. 42.86 ± 17.33 = 0.032 and 65.59 ± 26.68 vs. 37 ± 17.45 0.046, respectively).
We showed that microenvironment of cHL in adolescent patients is enriched with potential therapeutic targets of ICPI that may be considered for therapeutic applications. Furthermore, the presence of PD-1 expressing T-cells strongly relates to advanced stage disease and a low density of CD8+ T lymphocytes is associated with recurrence and progression of disease.
15至18岁青少年的经典型霍奇金淋巴瘤(cHL)显示出更高的疾病相关死亡率,总体预后比儿童和成人都差。
我们研究了青少年cHL患者亚组中的免疫检查点抑制剂(ICPIs)治疗靶点以及特定的调节性T细胞和细胞毒性T细胞亚群,并对它们的预后预测能力进行了验证。
我们获取了经福尔马林固定石蜡包埋(FFPE)的青少年cHL患者组织,通过免疫组织化学检测免疫检查点分子CTLA-4、LAG-3、PD-1和PDL1以及生物标志物FOXP3和CD8。
我们队列中的所有病例在微环境(ME)中均表达免疫检查点分子CTLA-4、LAG-3和PD-1,且PD1+细胞数量与晚期疾病密切相关,在III/IV期更高,表明其可能在cHL进展中起作用。诊断时CD8+微环境T细胞数量较少的患者复发和进展风险更高(分别为67.14±27.23对42.86±17.33,P = 0.032;65.59±26.68对37±17.45,P = 0.046)。
我们表明青少年cHL患者的微环境富含ICPIs的潜在治疗靶点,可考虑用于治疗应用。此外,表达PD-1的T细胞的存在与晚期疾病密切相关,而CD8+T淋巴细胞的低密度与疾病的复发和进展相关。